Cybin (NEO: CYBN) (NYSE American: CYBN) has released data from a pharmacokinetic study focused on evaluating CYB004, the company’s proprietary deuterated dimethyltryptamine (“DMT”) molecule (https://ibn.fm/nyCj8). The study analyzed delivery methods of CYB004, and showed initial data indicates significant advantages over Intravenous (“IV”) and Inhaled DMT.
“In many studies, DMT has shown to be a promising and effective psychedelic for the treatment of mental health issues,” said Cybin CEO Doug Drysdale. “However, known side effects like disorientation and anxiety and its mode of administration have historically hindered its use and availability. CYB004 via inhalation may solve these challenges and finally support a clinical path forward for this important therapeutic.”
According to the report, inhaled CYB004 showed significant advantages over both IV DMT and inhaled DMT, including longer duration of action and improved bioavailability. The study also indicated that inhaled CYB004 showed an onset of effect and dose profile similar to IV DMT. “These data may support the potential for inhalation as a viable and well-controlled delivery system of therapeutic psychedelics,” the announcement states, noting that Cybin is currently developing CYB004 for treatment of anxiety disorders.
Specifically, the company reported that, based on preclinical results, inhaled CYB004 demonstrated:
A new chemical entity, CYB004 is covered by a patent issued by the U.S. Patent and Trademark Office earlier this year. The patent allows claims that include a range of deuterated forms of DMT and 5-MeO-DMT. The composition of matter patent is expected to expire in 2041 before consideration of any patent term extensions.
“As part of Cybin’s overall mission to create safe and effective psychedelic-based therapeutics, inhaled CYB004 is being developed to potentially overcome the limitations of IV DMT and become an important treatment option for anxiety disorders for patients and physicians,” stated Drysdale. He also noted that the company plans to submit a regulatory filing for a pilot study in the coming weeks. “Cybin’s approach to psychedelic drug development enables the control of many biological factors, including improving the way a drug is metabolized and managing some adverse effects.
“In its natural form, DMT is unstable and not orally bioavailable,” Drysdale concluded. “Based on these preclinical studies, we believe CYB004 has the potential to overcome these issues. These results also provide strong evidence that an inhaled delivery mode may be able to address the limitations of IV DMT and could be widely applicable to a variety of psychedelics.”
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 888-902-4192 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
According to a recent study, individuals who have used classic psychedelics like LSD or psilocybin…
There is a growing trend in which parents take tiny doses of psychedelics like LSD…
Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to…
A new study has found that while all ethnic and racial groups can benefit from…
A new study that is yet to be peer-reviewed has found that rats given psilocybin…
The American embassy in Peru has warned Americans against taking traditional psychedelics like the ayahuasca…